# A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

> **NCT06611163** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 206 (actual)

## Conditions studied

- Moderate to Severe Genital Psoriasis

## Interventions

- **DRUG:** Tildrakizumab 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06611163
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2026-01-21
- **Final completion:** 2027-02
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611163, "A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT06611163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*